Format

Send to

Choose Destination
World J Gastroenterol. 2013;19(14):2154-61. doi: 10.3748/wjg.v19.i14.2154.

Clinicopathological features and outcomes of patients with gastric cancer: a single-center experience.

Author information

1
Medical Oncology, Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University, Cerrahpasa, 34300 Istanbul, Turkey. fsbiricik@yahoo.com

Abstract

AIM:

To evaluate the location, histopathology, stages, and treatment of gastric cancer and to conduct survival analysis on prognostic factors.

METHODS:

Patients diagnosed with of stomach cancer in our clinic between 2000 and 2011, with follow-up or a treatment decision, were evaluated retrospectively. They were followed up by no treatment, adjuvant therapy, or metastatic therapy. We excluded from the study any patients whose laboratory records lacked the operating parameters. The type of surgery in patients diagnosed with gastric cancer was total gastrectomy, subtotal gastrectomy or palliative surgery. Patients with indications for adjuvant treatment were treated with adjuvant and/or radio-chemotherapy. Prognostic evaluation was made based on the parameters of the patient, tumor and treatment.

RESULTS:

In this study, outpatient clinic records of patients with gastric cancer diagnosis were analyzed retrospectively. A total of 796 patients were evaluated (552 male, 244 female). The median age was 58 years (22-90 years). The median follow-up period was 12 mo (1-276 mo), and median survival time was 12 mo (11.5-12.4 mo). Increased T stage and N stage resulted in a decrease in survival. Other prognostic factors related to the disease were positive surgical margins, lymphovascular invasion, perineural invasion, cardio-esophageal settlement, and the levels of tumor markers in metastatic disease. No prognostic significance of the patient's age, sex or tumor histopathology was detected.

CONCLUSION:

The prognostic factors identified in all groups and the proposed treatments according to stage should be applied, and innovations in the new targeted therapies should be followed.

KEYWORDS:

Chemotherapy; Gastric carcinoma; New agents; Prognostic factors; Survival; Treatment

PMID:
23599641
PMCID:
PMC3627879
DOI:
10.3748/wjg.v19.i14.2154
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Baishideng Publishing Group Inc. Icon for PubMed Central
Loading ...
Support Center